֪ʶ¿ÆÆÕ|¼ä³äÖʸÉbjlƽ̨¡ª¡ªÉúÃüµÄÉñÆæÐÞ¸´Õß

ÈÕÆÚ£º01-22  µã»÷£º  ÊôÓÚ£ºÖªÊ¶¿ÆÆÕ
    ¸Ébjlƽ̨£¨Stem Cells£©£¬ÊÇÒ»ÖÖδ³ä·Ö·Ö»¯¡¢Éв»³ÉÊìµÄbjlƽ̨£¬¾ßÓÐ×ÔÎÒ¸üкͶàÏò·Ö»¯µÄDZÄÜ¡£ËüÃǾÍÏñÊÇÉúÃüµÄ“ÍòÄÜÖÖ×Ó”£¬ÔÚÌØ¶¨µÄÌõ¼þÏ£¬¿ÉÒÔ·Ö»¯Îª¸÷ÖÖ²»Í¬ÀàÐ͵Äbjlƽ̨£¬ÎªÈËbjlƽ̨¹ÙÍøµÄÐÞ¸´ºÍÔÙÉúÌṩÁËÎÞÏÞ¿ÉÄÜ¡£¸Ébjlƽ̨°´ÕÕ·Ö»¯Ç±ÄÜ¿ÉÒÔ·ÖΪȫÄܸÉbjlƽ̨¡¢¶àÄܸÉbjlƽ̨¡¢µ¥ÄܸÉbjlƽ̨¡£
    ¼ä³äÖʸÉbjlƽ̨£¨Mesenchymal Stem Cells£¬MSC£©ÊÇÒ»ÖÖ¶àÄܸÉbjlƽ̨£¬¾ßÓÐ×ÔÎÒ¸üкͶàÏò·Ö»¯µÄÄÜÁ¦¡£Ëü¿ÉÒÔ´Ó¶àÖÖ×éÖ¯ÖлñÈ¡£¬Èç¹ÇËè¡¢Ö¬·¾¡¢Æê´øµÈ¡£MSCs¾ßÓжàÖÖÉúÎïѧ¹¦ÄÜ£¬°üÀ¨¿¹Ñס¢¿¹µòÍö¡¢Éñ¾­±£»¤¡¢Ñª¹ÜÉú³É¡¢µ÷½ÚÃâÒߵȡ£ÕâЩССµÄbjlƽ̨Ô̺¬×ž޴óµÄDZÁ¦£¬ÎªÈËÀཡ¿µ´øÀ´ÁËеÄÏ£Íû¡£

 

¼ä³äÖʸÉbjlƽ̨ËÄ´ó¹¦ÄÜ£º

Ò»¡¢×éÖ¯ÔÙÉúÓëÆ÷¹ÙÐÞ¸´

MSC×÷Ϊ¶àÄܸÉbjlƽ̨£¬ËäÎÞ·¨·¢Óý³ÉÍêÕûµÄ¸öbjlƽ̨¹ÙÍø£¬È´¾ßÓзֻ¯³ÉÈËbjlƽ̨¹ÙÍø¶àÖÖbjlƽ̨µÄDZÄÜ£¬ÕâЩÑÜÉúbjlƽ̨¼ÈÓÐÍûÌæ»»¡¢ÐÞ¸´ÊÜËðµÄbjlƽ̨£¬Ò²¿ÉÒԴ̼¤bjlƽ̨¹ÙÍøÄڵĸÉbjlƽ̨£¬ÒÔ¹²Í¬Íê³É×éÖ¯ÔÙÉúµÄ¹ý³Ì¡£

¡÷ÔÚºÏÊʵÄÓÕµ¼Ï£¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ·Ö»¯Îª¶àÖÖÈËbjlƽ̨¹ÙÍøÄÚµÄbjlƽ̨

1.¹Ç÷Àϵͳ£º
    ¶ÔÓÚ¹ÇÕÛ»¼Õߣ¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ´Ù½ø¹ÇðèÐγɣ¬¼ÓËÙ¹ÇÕÛÓúºÏ¡£ËüÃÇÄܹ»·Ö»¯Îª³É¹Çbjlƽ̨£¬·ÖÃڹǻùÖʳɷÖ£¬Ôö¼Ó¹ÇÃܶȺÍÇ¿¶È[1]¡£
    ÔڹǹؽÚÑ׵ȹؽڼ²²¡ÖУ¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔÐÞ¸´ÊÜËðµÄ¹Ø½ÚÈí¹Ç£¬¼õÇáÌÛÍ´£¬¸ÄÉÆ¹Ø½Ú¹¦ÄÜ¡£Í¨¹ý·ÖÃÚÉú³¤Òò×ÓºÍbjlƽ̨Òò×Ó£¬ËüÃÇ»¹¿ÉÒÔÒÖÖÆÑ×Ö¢·´Ó¦£¬¼õÉÙÈí¹Çbjlƽ̨µÄµòÍö[2]¡£
2.ÐÄѪ¹Üϵͳ£º

¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ·Ö»¯ÎªÐļ¡bjlƽ̨ºÍѪ¹ÜÄÚÆ¤bjlƽ̨£¬´Ù½øÐļ¡ÔÙÉúºÍѪ¹ÜÐÂÉú¡£ÔÚÐ£ËÀµÈÐÄÔ༲²¡ÖУ¬ÒÆÖ²¼ä³äÖʸÉbjlƽ̨¿ÉÒÔËõС¹£ËÀÃæ»ý£¬¸ÄÉÆÐÄÔ๦ÄÜ£¬½µµÍÐÄÁ¦Ë¥½ßµÄ·¢ÉúÂÊ¡£

¶ÔÓÚÍâÖÜѪ¹Ü¼²²¡£¬È綯ÂöÓ²»¯±ÕÈûÖ¢£¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ´Ù½ø²àÖ§Ñ­»·µÄ½¨Á¢£¬¸ÄÉÆÖ«bjlƽ̨¹ÙÍøÈ±ÑªÖ¢×´¡£
3.Æ÷¹ÙÒÆÖ²£º

ÔÚÆ÷¹ÙÒÆÖ²ÖУ¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔÓÕµ¼ÃâÒßÄÍÊÜ£¬½µµÍÒÆÖ²ÅųⷴӦµÄ·¢ÉúÂÊ¡£ËüÃÇ¿ÉÒÔµ÷½ÚÒÆÖ²ÊÜÕßµÄÃâÒßϵͳ£¬´Ù½ø¹©bjlƽ̨¹ÙÍøÆ÷¹ÙµÄ´æ»îºÍ¹¦Äָܻ´¡£

¼ä³äÖʸÉbjlƽ̨»¹¿ÉÒÔͨ¹ý·ÖÃÚÉú³¤Òò×ÓºÍbjlƽ̨Òò×Ó£¬´Ù½øÒÆÖ²Æ÷¹ÙµÄѪ¹ÜÐÂÉúºÍ×éÖ¯ÐÞ¸´[3]¡£

 

¶þ¡¢ÃâÒßµ÷½Ú

MSC¶ÔÏÈÌìÃâÒߺͻñµÃÐÔÃâÒß¾ùÓÐÒ»¶¨µÄÃâÒßµ÷½Ú»úÖÆ¡£Ëü¿ÉÒÔͨ¹ýbjlƽ̨Óëbjlƽ̨¼äµÄÖ±½Ó½Ó´¥£¬ÒÔ¼°·ÖÃÚÉúÎï»îÐÔÒò×Ó£¬ÈçÉú³¤Òò×Ó¡¢bjlƽ̨Òò×ÓºÍÇ÷»¯Òò×ӵȷ¢»ÓÆäÃâÒßµ÷½Ú×÷Óá£
1.×ÔÉíÃâÒßÐÔ¼²²¡£º
    ¼ä³äÖʸÉbjlƽ̨¿ÉÒÔÒÖÖÆ¹ý¶È»îÔ¾µÄÃâÒßϵͳ£¬µ÷½ÚÃâÒßbjlƽ̨µÄ¹¦ÄÜ¡£ÔÚÀà·çʪÐԹؽÚÑס¢ÏµÍ³ÐÔºì°ßÀÇ´¯¡¢¶à·¢ÐÔÓ²»¯Ö¢µÈ×ÔÉíÃâÒßÐÔ¼²²¡ÖУ¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ¼õÇáÑ×Ö¢·´Ó¦£¬»º½â¼²²¡Ö¢×´¡£
2.Éñ¾­ÏµÍ³£º
    ÔÚÉñ¾­ÏµÍ³ËðÉËÖУ¬ÈçÄÔ×äÖкͼ¹ËèËðÉË£¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ·ÖÃÚÉñ¾­ÓªÑøÒò×Ó£¬´Ù½øÉñ¾­bjlƽ̨µÄ´æ»îºÍÔÙÉú¡£ËüÃÇ»¹¿ÉÒÔµ÷½ÚÃâÒß·´Ó¦£¬¼õÇáÑ×Ö¢ËðÉË£¬´Ù½øÉñ¾­¹¦ÄܵĻָ´¡£
    ¶ÔÓÚÉñ¾­ÍËÐÐÐÔ¼²²¡£¬ÈçÅÁ½ðÉ­²¡ºÍ°¢¶û´Äº£Ä¬²¡£¬¼ä³äÖʸÉbjlƽ̨¿ÉÄÜͨ¹ý·ÖÃÚ¶àÖÖÉúÎï»îÐÔÎïÖÊ£¬¸ÄÉÆÉñ¾­ÔªµÄ´úлºÍ¹¦ÄÜ£¬ÑÓ»º¼²²¡µÄ½øÕ¹[4]¡£

 

Èý¡¢¿¹µòÍö

µòÍöÊÇË¥ÀϵĽá¹û£¬ËüÒâζ×Åbjlƽ̨ÒѾ­É¥Ê§Á˽øÒ»²½µÄ·ÖÁÑ¡¢ÔÙÉúÄÜÁ¦£¬¼´½«³ÉΪÉíbjlƽ̨¹ÙÍøµÄ¸ºµ£¡£¶ø¸Ébjlƽ̨¾ßÓп¹µòÍöµÄ×÷Ó㬲»µ«ÄÜÒÔ“ÖÖ×Óbjlƽ̨”µÄÉí·Ý²¹³äÀÏ»¯¡¢ËÀÍöµÄbjlƽ̨£¬»¹ÄÜͨ¹ýÅÔ·ÖÃÚЧӦ£¬·ÖÃÚÉú³¤Òò×Ó£¨ÈçVEGF¡¢EGF¡¢FGF£©¡¢¿¹µòÍöÒò×Ó£¨ÈçVEGF165¡¢FGF-2¡¢HGFµÈ£©×èÖ¹³ÉÊìµÄ¹¦ÄÜbjlƽ̨¹ýÔç¡¢¹ý¿ìµØÆô¶¯Ë¥ÀϵijÌÐò¡£
1.Ƥ·ô¿¹Ë¥ÀÏ£º

¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ·ÖÃÚ½ºÔ­µ°°×¡¢µ¯ÐÔµ°°×ºÍ͸Ã÷ÖÊËáµÈ£¬Ôö¼ÓƤ·ôµÄµ¯ÐÔºÍË®·Öº¬Á¿£¬¼õÉÙÖåÎÆºÍÉ«°ßµÄÐγÉ¡£

ËüÃÇ»¹¿ÉÒÔ´Ù½øÆ¤·ôbjlƽ̨µÄÔöÖ³ºÍ·Ö»¯£¬¸ÄÉÆÆ¤·ôµÄг´úл£¬ÑÓ»ºÆ¤·ôË¥ÀϵĹý³Ì¡£
2.Æ÷¹Ù¹¦ÄܸÄÉÆ£º

Ëæ×ÅÄêÁäµÄÔö³¤£¬ÈËbjlƽ̨¹ÙÍø¸÷¸öÆ÷¹ÙµÄ¹¦ÄÜÖð½¥Ë¥ÍË¡£¼ä³äÖʸÉbjlƽ̨¿ÉÒÔͨ¹ý·ÖÃÚÉú³¤Òò×ÓºÍbjlƽ̨Òò×Ó£¬¸ÄÉÆÆ÷¹ÙµÄ΢»·¾³£¬´Ù½øbjlƽ̨µÄÔÙÉúºÍÐÞ¸´£¬Ìá¸ßÆ÷¹ÙµÄ¹¦ÄÜ¡£ÀýÈçÔÚ¸ÎÔà¡¢ÉöÔàºÍ·ÎµÈÆ÷¹ÙÖУ¬¼ä³äÖʸÉbjlƽ̨¿ÉÒÔ¼õÇá×éÖ¯ËðÉË£¬¸ÄÉÆÆ÷¹Ù¹¦ÄÜ¡£

2024 Äê 9 Ô 13 ÈÕ£¬Öйú¿ÆÑÐÈËÔ±ÔÚÐÐbjlƽ̨¹ÙÍøÆÚ¿¯SignalTransduction and Targeted TherapyÉÏ·¢±íÁËÌâΪ“Pharmacokinetic characteristics of mesenchymal stemcells in translational challenges”µÄ×ÛÊö±¨¸æ£¬±¨¸æÁ˼ä³äÖʸÉbjlƽ̨µÄÁÙ´²Ñо¿½øÕ¹[5]½ØÖÁ2023ÄêÄê12Ô£¬ÔÚ ClinicalTrials.gov ÉÏʹÓùؼü×Ö“¼ä³äÖʸÉbjlƽ̨”½øÐмìË÷£¬»á·¢ÏÖ 1600 ¶àÏîÏà¹ØÁÙ´²ÊÔÑ飬ÆäÖÐ 1500 ¶àÏîÁÙ´²ÊÔÑé²ÉÓà MSCs ×÷ΪÖÎÁƸÉÔ¤¡£×Übjlƽ̨¹ÙÍø¶øÑÔ£¬MSCs ÄÍÊÜÐÔÁ¼ºÃ£¬´ó¶àÊýÊÔÑ鱨¸æ³ÆÖÐÆÚûÓв»Á¼·´Ó¦¡£Ö»ÓÐÉÙÊýÊÔÑé±íÃ÷ÔÚ×¢ÉäÆÚ¼äÓÐÇá΢ºÍ¶ÌÔݵIJ»Á¼·´Ó¦¡£

¡÷Ŀǰ¼ä³äÖʸÉbjlƽ̨ÁÆ·¨ÁÙ´²ÊÔÑéÖеÄÃâÒߺÍÑ×Ö¢¼²²¡ÊÊÓ¦Ö¢

ÖÚ¶àÒÑÍê³ÉµÄÁÙ´²ÊÔÑéÖ¤Ã÷ÁËMSCÊä×¢¶ÔÖÎÁƶàÖÖ¼²²¡µÄÁÆÐ§£¬ÀýÈçÒÆÖ²ÎËÞÖ÷²¡£¨GvHD£©¡¢¶à·¢ÐÔÓ²»¯Ö¢(MS)¡¢¿ËÂÞ¶÷²¡(CD)¡¢¼¡Î®Ëõ²àË÷Ó²»¯Ö¢(ALS)¡¢Ð£ËÀ(MI)¡¢ÌÇÄò²¡£¨DM£©ºÍ¼±ÐÔºôÎü¾½ÆÈ×ÛºÏÕ÷(ARDS)µÈ[6]¡£ÔÚÕâЩÁÙ´²ÊÔÑéÖУ¬MSCÖÎÁÆ“Éñ¾­”¼²²¡(17%)ºÍ“¹Ø½Ú”¼²²¡(15%)ÊÇ×¢²áÊÊÓ¦Ö¢ÖÐ×î³£¼ûµÄ¡£ÐÄѪ¹Ü¼²²¡(8.8%)ºÍGvHD(8.3%)Óë¸Ã¼²²¡ÃÜÇÐÏà¹Ø£¬IIIÆÚÁÙ´²ÊÔÑéµÄ±ÈÀý¸ü¸ß¡£ÓÐ84%µÄMSCÁÙ´²ÊÔÑéÃ÷È·Ö¸¶¨Á˸øÒ©Í¾¾¶¡£

 

 

MSCÖÎÁÆÉñ¾­ÏµÍ³¼²²¡µÄÁÙ´²°¸Àý

1.̱»¾
   Öйú»ªÎ÷bjlƽ̨¹ÙÍøÔº°¸Àý£ºËÄ´¨´óѧ»ªÎ÷bjlƽ̨¹ÙÍøÔºÔø¶ÔÒ»ÃûÒòÍæ»¬ÏèÉ¡¶ø¸ß×¹µ¼ÖÂÈ«Éí̱»¾µÄÖÐÄêÄÐÊ¿½øÐÐÁË“Æê´ø¼ä³äÖʸÉbjlƽ̨”ÖÎÁÆ¡£ÕâÊÇbjlƽ̨¹ÙÍøÔº¿ªÕ¹µÄ¸Ébjlƽ̨ÖÎÁƼ¹ËèËðÉËÁÙ´²Ñо¿¿ÎÌâµÄÒ»²¿·Ö¡£°´ÕÕÖÎÁƼƻ®£¬»¼ÕßÐè×¢Éä4´Î¸Ébjlƽ̨£¬Ã¿Á½´Î×¢Éä¼ä¸ôÒ»¸öÔ¡£ÔÚǰÆÚÑо¿ÖУ¬ÖÐɽ´óѧ¸½ÊôµÚÈýbjlƽ̨¹ÙÍøÔºµÄʵÑéЧ¹ûÏÔÖø£¬Ò»Ãû³¤ÆÚ×øÂÖÒεĽØÌ±»¼Õß¾­¹ý3´Î¸Ébjlƽ̨עÉäÖÎÁƺó£¬ÒѾ­Äܹ»Õ¾Á¢ÆðÀ´¡£

2. ÄÔ×äÖÐ
     Ò»Ïî·¢±íÔÚ¡¶Frontiers in Medicine¡·µÄÑо¿±¨µÀÁË5ÃûÄêÁäÔÚ46ÖÁ70ËêÖ®¼äÇÒÓÐÖз粡ʷµÄ»¼Õß½ÓÊÜÆê´ø¼ä³äÖʸÉbjlƽ̨ÖÎÁƵÄÇé¿ö¡£Ã¿Î»»¼Õß½ÓÊÜ1–2×10?¸öÆê´ø¼ä³äÖʸÉbjlƽ̨¡£ÖÎÁƺ󣬻¼ÕßÒòÄÔ×äÖгöÏÖµÄÖ«bjlƽ̨¹ÙÍøÎÞÁ¦»òÎÞ·¨»î¶¯µÈÇé¿ö¶¼µÃµ½ÏÔÖø¸ÄÉÆ£¬Éú»îÖÊÁ¿Ìá¸ß¡£Ò»Ãû46ËêµÄÄÐÐÔ»¼Õߣ¬ÔÚÄÔ×äÖкó7¸öÔ½ÓÊÜÖÎÁÆ£¬4ÖܺóÓÒÊÖÎÞÁ¦Çé¿ö¿ªÊ¼¸ÄÉÆ£¬3¸öÔºóÓÒÊÖºÍÉÏÖ«ÎÞÁ¦Çé¿öÏÔÖø¸ÄÉÆ£»Ò»Ãû60ËêµÄÅ®ÐÔ»¼Õߣ¬ÔÚÖзçºóµÚ¶þÖܽÓÊÜÖÎÁÆ£¬12¸öÔºóÍÌÑÊ·´Éä»Ö¸´£¬×óÊÖÎÕÁ¦»Ö¸´£¬×óÍÈõËÐÐÃ÷ÏÔ¸ÄÉÆ£¬×óÁ³¹¦Äָܻ´Õý³£[7]¡£
3.ÅÁ½ðÉ­
    °Ý¶ú¼¯Íż°ÆäÆìϵÄbjlƽ̨ÖÎÁÆ×Ó¹«Ë¾Ôø½øÐйýÒ»ÖÖÅÁ½ðÉ­²¡Ç±ÔÚÊ×´´bjlƽ̨ÁÆ·¨µÄIÆÚÁÙ´²ÊÔÑé¡£¸ÃÁÆ·¨Ê¹ÓõÄÒ©ÎïBemdaneprocel£¨BRT-DA01£©ÏÔʾ³öÁËÁ¼ºÃµÄÄÍÊÜÐÔ£¬ÇÒûÓз¢ÉúÖØ´ó°²È«Ê¼þ£¬Í¬Ê±Õ¹Ê¾ÁËÒÆÖ²µÄ¿ÉÐÐÐÔÒÔ¼°bjlƽ̨ÔÚ´óÄÔÖдæ»îºÍÖ²ÈëÒ»ÄêµÄÖ¤¾Ý¡£
4.°¢¶û´Äº£Ä¬Ö¢
    º«¹úÊ×¶ûÈýÐÇbjlƽ̨¹ÙÍøÁÆÖÐÐÄÕÐļÁ˾ÅÃûÇá¶ÈÖÁÖжȰ¢¶û´Äº£Ä¬²¡³Õ´ôÖ¢»¼Õߣ¬ÈýÃû»¼Õß½ÓÊܵͼÁÁ¿£¨1000Íòbjlƽ̨/2mL£©£¬6Ãû»¼Õß½ÓÊܸ߼ÁÁ¿£¨3000Íòbjlƽ̨/2mL£©¡£9Ãû»¼Õß½øÐÐÁËÈý´Î¸Ébjlƽ̨עÉ䣨ÿ¸ô4ÖÜÒ»´Î£©¡£ÔÚÖ®ºó³¤´ï36¸öÔµĸú×ÙÑо¿ÆÚ¼ä£¬ Ã»Óл¼Õß³öÏÖÑÏÖØµÄ²»Á¼Ê¼þ¡£Óɴ˿ɼû£¬¸Ébjlƽ̨ÖÎÁư¢¶û×Ⱥ£Ä¬Ö¢ÊÇ¿ÉÐС¢°²È«ÇÒÄÍÊÜÐÔÁ¼ºÃµÄ[8]¡£

 

¼ä³äÖʸÉbjlƽ̨µÄÓ¦ÓÃǰ¾°Ê®·Ö¹ãÀ«¡£Ä¿Ç°£¬¿ÆÑ§¼ÒÃÇÕýÔÚ½øÐдóÁ¿µÄÑо¿ºÍÁÙ´²ÊÔÑ飬̽Ë÷ÆäÔÚ¸ü¶à¼²²¡ÖÎÁÆÖеÄDZÁ¦¡£ËäÈ»¼ä³äÖʸÉbjlƽ̨ÁÆ·¨ÈÔÃæÁÙһЩÌôÕ½£¬È簲ȫÐÔ¡¢ÓÐЧÐԺͱê×¼»¯µÈÎÊÌ⣬µ«Ëæ×ż¼ÊõµÄ²»¶Ï½ø²½£¬ÎÒÃÇÓÐÀíÓÉÏàÐÅ£¬Î´À´¼ä³äÖʸÉbjlƽ̨ÖÎÁƸ÷À༲²¡½«»áÈ¡µÃ¸ü´óµÄÍ»ÆÆ¡£

 

²Î¿¼ÎÄÏ×£º

[1] Kimura K, Breitbach M, Schildberg FA, Hesse M, Fleischmann BK. Bone marrow CD73+ mesenchymal stem cells display increased stemness in vitro and promote fracture healing in vivo. Bone Rep. 2021 Sep 29;15:101133.

[2] ÀîÔóÇÙ,Ñî¼ÑÃ÷,¸ß·å,µÈ.¼ä³äÖʸÉbjlƽ̨´Ù½øÈí¹ÇÐÞ¸´ÖÎÁƹǹؽÚÑ׵ĻúÖÆ¼°Ó¦ÓýøÕ¹[J].ɽ¶«bjlƽ̨¹ÙÍøÒ©,2023,63(22):86-90.

[3] ÇñìϳÌ,ÖÜÏÔÓñ,Áõ·Æ,µÈ.¼ä³äÖʸÉbjlƽ̨¼°ÆäÍâÃÚbjlƽ̨¹ÙÍøÔÚÒÆÖ²ÖеÄÓ¦ÓýøÕ¹[J].×éÖ¯¹¤³ÌÓëÖØ½¨Íâ¿Æ,2023,19(02):184-188.

[4] [1]ÐíÑÞ,Ф½¨»Ô.¼ä³äÖʸÉbjlƽ̨ÖÎÁÆË¥ÀÏÏà¹Ø¼²²¡µÄÑо¿½øÕ¹[J].ÖйúÀÏÄêѧÔÓÖ¾,2023,43(13):3310-3314.

[5] Shan Y, Zhang M, Tao E, Wang J, Wei N, Lu Y, Liu Q, Hao K, Zhou F, Wang G. Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges. Signal Transduct Target Ther. 2024 Sep 13;9(1):242.

[6] Wang LT, Liu KJ, Sytwu HK, Yen ML, Yen BL. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl Med. 2021 Sep;10(9):1288-1303.

[7] Ercelen N, Karasu N, Kahyaoglu B, Cerezci O, Akduman RC, Ercelen D, Erturk G, Gulay G, Alpaydin N, Boyraz G, Monteleone B, Kural Z, Silek H, Temur S, Bingol CA. Clinical experience: Outcomes of mesenchymal stem cell transplantation in five stroke patients. Front Med (Lausanne). 2023 Jan 19;10:1051831.

[8] Kim HJ, Cho KR, Jang H, Lee NK, Jung YH, Kim JP, Lee JI, Chang JW, Park S, Kim ST, Moon SW, Seo SW, Choi SJ, Na DL. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial. Alzheimers Res Ther. 2021 Sep 14;13(1):154.

 

ÃâÔðÉùÃ÷£ºÉîÛÚbjlƽ̨¹ÈÖÂÁ¦ÓÚÑо¿bjlƽ̨Óë»ùÒòÁÆ·¨£¬ÎªÍƶ¯ÐÂÐ˼¼Êõ£¬Èøü¶àÈËÁ˽âÉúÎïbjlƽ̨¹ÙÍøÒ©Ð·¢Õ¹¡£±¾ÎÄÄÚÈݽö×÷ÐÅÏ¢½»Á÷ʹÓ㬱¾Æ½Ì¨¶ÔÎÄÖÐÄÚÈÝ¡¢³ÂÊö¡¢¹ÛµãÅжϱ£³ÖÖÐÁ¢£¬²»´ú±íÉîÛÚbjlƽ̨¹ÈÁ¢³¡ºÍ¹Ûµã¡£±¾ÎÄÏà¹ØÐÅÏ¢²»µÃÓÃ×÷Õï¶Ï»òÖÎÁÆ£¬²»ÄÜ´úÌæ×¨bjlƽ̨¹ÙÍøbjlƽ̨¹ÙÍøÑ§Òâ¼û£¬±¾¹«ÖÚÆ½Ì¨½«²»³Ðµ£ÈκÎÔðÈΡ£ÒÔÉÏÉùÃ÷ÄÚÈݵÄ×îÖÕ½âÊÍȨ¹é±¾¹«ÖÚÆ½Ì¨ËùÓУ¬±¾ÉùÃ÷½«ÊÊÓñ¾Æ½Ì¨ËùÓÐʱ¼ä·ÖÏíµÄÎÄÕ£¬Ð»Ð»ºÏ×÷£¡

°æÈ¨ËµÃ÷£ºÎÄÕ°æÈ¨¹éÉîÛÚbjlƽ̨¹ÈËùÓУ¬»¶Ó­¸öÈËת·¢ÖÁÅóÓÑȦ£¬Ã½bjlƽ̨¹ÙÍø»ò»ú¹¹ÔÚδ¾­ÊÚȨÏ£¬ÒÔÈκÎÐÎÊ½×ªÔØµ½ÆäËûƽ̨£¬½«ÊÓΪÇÖȨ¡£×ªÔØÊÚȨÇëÔÚ¡¸ÉîÛÚbjlƽ̨¹È¡¹Î¢ÐŹ«ÖںŻظ´“×ªÔØ”£¬»ñÈ¡×ªÔØÐëÖª¡£

 

ÍùÆÚÍÆ¼ö  //

 

֪ʶ¿ÆÆÕ|ÍâÃÚbjlƽ̨¹ÙÍø——¿¹Ë¥¡¢µÝËÍСÄÜÊÖ

֪ʶ¿ÆÆÕ | APUNK™——·Ç»ùÒòÐÞÊÎͬÖÖÒìbjlƽ̨¹ÙÍøNKbjlƽ̨²úÆ·

֪ʶ¿ÆÆÕ | °ÐÏòBCMAµÄCAR-TÑо¿½øÕ¹

֪ʶ¿ÆÆÕ | ÁÙ´²Ó¦ÓÃCAR-TµÈbjlƽ̨²úÆ·ºóµÄ²»Á¼·çÏÕÓÐЧ¿ØÖÆ£¨Ï£©

¹ØÓÚÉîÛÚbjlƽ̨¹È

ÉîÛÚbjlƽ̨¹ÈÉúÎïbjlƽ̨¹ÙÍøÒ©ÓÐÏÞ¹«Ë¾£¨Ï³Æ:ÉîÛÚbjlƽ̨¹È£©ÊǹúÄÚΨһһ¼Ò¿ÉÌṩ¹¤bjlƽ̨¹ÙÍø¼¶Äæ×ªÂ¼²¡¶¾ÔØbjlƽ̨¹ÙÍøµÄbjlƽ̨Óë»ùÒòÖÎÁÆÒ»Õ¾Ê½½â¾ö·½°¸·þÎñÉÌ£¬ÓÉÀ´×ÔÃÀ¹ú¹þ·ð´óѧºÍ¼ÓÖÝ´óѧʥµü¸ê·ÖУµÈº£¹é¿ÆÑ§¼ÒÁªºÏ´´°ì£¬ÓµÓйúÄÚÊ×ÅúÕÆÎÕ¹¤bjlƽ̨¹ÙÍø¼¶Äæ×ªÂ¼²¡¶¾ÔØbjlƽ̨¹ÙÍø¼¼Êõ£¨PackRV-SSϵͳ£©µÄÑз¢Éú²úÍŶÓ¡£ÉîÛÚbjlƽ̨¹ÈÒѽ¨³É¹æ·¶»¯£¬±ê×¼»¯£¬¹¤bjlƽ̨¹ÙÍø»¯Éú²úGMP¼¶Äæ×ªÂ¼²¡¶¾ÔØbjlƽ̨¹ÙÍø¼°CAR-TµÈbjlƽ̨²úÆ·¹ÜÏߣ¬ÒÑÔÚÉîÛÚ¡¢±±¾©ºÍÖÐɽÈýµØ½¨Á¢²úbjlƽ̨¹ÙÍøÁª¶¯£¬½¨³É¹²¼Æ³¬Íòƽ·ûºÏ¹ú¼ÊGMP±ê×¼µÄÉú²ú³µ¼ä¼°Ñз¢ÊµÑéÊÒ¡£ÉîÛÚbjlƽ̨¹È´Ó²¡¶¾ÔØbjlƽ̨¹ÙÍø¹ÜÏߣ¬µ½bjlƽ̨²úÆ·¹ÜÏߣ¬ÔÙµ½IIT/IND/NDA¸¨ÖúÉ걨£¬ÔÙµ½ÐÐbjlƽ̨¹ÙÍøÄÚÈ˲ÅÅàÑøÒѽ¨Á¢³ÉÊìµÄÈ«Á÷³Ì¡¢Ò»Õ¾Ê½Î¯ÍзþÎñ£¬½¨ÓÐÄæ×ªÂ¼²¡¶¾¡¢Âý²¡¶¾µÈ¶àÖÖ²¡¶¾ÔØbjlƽ̨¹ÙÍøÉú²ú¹ÜÏß¼°CAR-T¡¢CAR-NK¡¢TCR-TµÈbjlƽ̨Éú²ú¹ÜÏß¡£Í¬Ê±ÓëÉóÆÀ¼ìÑé»ú¹¹¡¢¿ÆÑÐÔºËù¡¢bjlƽ̨¹ÙÍøÔººÍÐÐbjlƽ̨¹ÙÍøÁúÍ·Æóbjlƽ̨¹ÙÍøÉî¶ÈºÏ×÷£¬ÌṩIIT¡¢IND¸¨ÖúÉ걨·þÎñ¡£

ÉîÛÚbjlƽ̨¹ÈÊÇÉîÛÚÊÐÉúÎïbjlƽ̨¹ÙÍøÒ©²úbjlƽ̨¹ÙÍøÖØ´ó¹«¹²·þÎñƽ̨¡¢ÉîÛÚÊÐÖØ´óÏîÄ¿¡¢ÉîÛÚÊиßÐÂÇø·¢Õ¹×¨Ïî¼Æ»®´´ÐÂÆ½Ì¨³É¹û²úbjlƽ̨¹ÙÍø»¯»ùµØ¡¢“¾ÛÁúÁì¾üÈ˲ŔDÀà¸ß³É³¤ÐÔÆóbjlƽ̨¹ÙÍø¡¢bjlƽ̨²úbjlƽ̨¹ÙÍø¹Ø¼ü¹²ÐÔ¼¼Êõ¹ú¼Ò¹¤³ÌÑо¿ÖÐÐIJ¡¶¾ÔØbjlƽ̨¹ÙÍø¹²ÐÔ¼¼ÊõÑо¿Æ½Ì¨¡¢ÖйúʳƷҩƷÆóbjlƽ̨¹ÙÍøÖÊÁ¿°²È«´Ù½ø»á¸±»á³¤µ¥Î»¡¢ÉîÛÚÊÐbjlƽ̨¹ÙÍøÑ§Ñо¿×¨Ïî×ʽðÒÀÍе¥Î»¡¢ÉîÛÚÊÐÉúÎïbjlƽ̨¹ÙÍøÒ©²ú½ÌÁªÃ˸±Àíʳ¤µ¥Î»¡¢È«¹úÉúÎï¼¼ÊõÐÐbjlƽ̨¹ÙÍø²ú½ÌÈںϹ²Í¬bjlƽ̨¹ÙÍø³£ÎñÀíʵ¥Î»¡¢ÉîÛÚÊÐÉúÎïbjlƽ̨¹ÙÍøÒ©´Ù½ø»áÀíʵ¥Î»¡¢2022Äê¶ÈÆºÉ½Çø“Ê®´ó´´ÐÂÆ½Ì¨”¡¢¿Æ¼¼ÐÍÖÐСÆóbjlƽ̨¹ÙÍø¡¢´´ÐÂÐÍÖÐСÆóbjlƽ̨¹ÙÍø¡¢ÉîÛÚÊÐÆºÉ½Çø´óѧÉúʵϰ»ùµØ£¬ÈÙ»ñ2024Äê¶ÈÑÇÌ«Çøbjlƽ̨Óë»ùÒòÖÎÁÆÐÐbjlƽ̨¹ÙÍøÖ®ÐÇ“×î¼Ñ¼¼ÊõÍ»ÆÆ½±”¡¢µÚÊ®¶þ½ìÖйú´´Ð´´bjlƽ̨¹ÙÍø´óÈüÓÅÐãÆóbjlƽ̨¹ÙÍø½±¡¢Öйú´´½»»á´´Ð´´bjlƽ̨¹ÙÍø´óÈüÈýµÈ½±¡¢CGTÁìÓòCDMOºÏ×÷ÆôÃ÷Ðǽ±¡£

×óÓÒ»¬¶¯¿Éä¯ÀÀ¸ü¶àͼƬ

END

 

΢ÐŹ«ÖÚºÅ

Êг¡²¿£ºËïŮʿ

bjlƽ̨»ÝÖÚÉú »ùÒò´´Î´À´

 Á˽â¸ü¶àÄÚÈÝÇëµÇ¼  

www.sz-cell.com

È«¹úͳһ·þÎñÈÈÏß

400-800-1266

 

΢ÐŹ«ÖÚºÅ
ɨһɨ£¬¹Ø×¢ÎÒÃÇ×îÐÂÏûϢɨһɨ£¬¹Ø×¢ÎÒÃÇ×îÐÂÏûÏ¢
ÁªÏµÎÒÃÇ
400-800-1266

¹¤×÷ʱ¼ä£ºÖÜÒ»ÖÁÖÜÎå 9:00-18:00

ÁªÏµÈË£ºÀµÅ®Ê¿

ÊÖ»ú£º13670105633

Óʼþ£ºlaijiaqi@sz-cell.com

µØÖ·£ºÉîÛÚÊÐÆºÉ½Çø¿Óè÷½ÖµÀ½ðɳÉçÇøÈÙÌï·1ºÅº£ÆÕÈðÉúÎïbjlƽ̨¹ÙÍøÒ©Éú̬԰

µ×²¿µ¼º½
ÉîÛÚbjlƽ̨¹ÈÉúÎïbjlƽ̨¹ÙÍøÒ©ÓÐÏÞ¹«Ë¾ÊÇÖйúÒ»¼ÒרעÓÚbjlƽ̨ºÍ»ùÒòÖÎÁƲúbjlƽ̨¹ÙÍøÁìÓòµÄһվʽ×ÛºÏÍâ°ü·þÎñÉÌ£¬Ò²ÊǹúÄÚÊ×Åú¾ß±¸ÁÙ´²¼¶Ä没¶¾ÔØbjlƽ̨¹ÙÍøGMP¹¤bjlƽ̨¹ÙÍø»¯Éú²úµÄCRO/CDMO¹«Ë¾¡£ ÉîÛÚbjlƽ̨¹ÈÊÇÉîÛÚÊÐÖØ´óCRO/CDMO¹«¹²¼¼Êõ·þÎñƽ̨½¨ÉèÏîÄ¿£¬Ò²ÊÇÉîÛÚÊÐ×îй«²¼µÄ20+8Õ½ÂÔÐÔÐÂÐ˲úbjlƽ̨¹ÙÍøÏîÄ¿¡£ÉîÛÚbjlƽ̨¹È¾ßÓй淶»¯£¬±ê×¼»¯£¬¹¤bjlƽ̨¹ÙÍø»¯Éú²úGMP¼¶CAR-TµÈbjlƽ̨²úÆ·µÄÄÜÁ¦£¬Ö÷Òª½¨ÓÐCAR-T¡¢CAR-NK¡¢CAR-M¡¢¦Ã¦ÄT¡¢TIL¡¢TCR-TµÈbjlƽ̨²úÆ·Éú²úÏߣ¬Ä没¶¾¡¢Âý²¡¶¾¡¢·Ç²¡¶¾ÔØbjlƽ̨¹ÙÍø¡¢AAVµÈ¶àÖÖ²¡¶¾ÔØbjlƽ̨¹ÙÍøÒÔ¼°ÍâÃÚbjlƽ̨¹ÙÍø¡¢»ùÒò¹¤³Ì¿¹bjlƽ̨¹ÙÍø¡¢bjlƽ̨Òò×Ó¡¢ÈÜÁö²¡¶¾¡¢ÒßÃçµÈÒ©Æ·Éú²úµÄbjlƽ̨ԭÁϲúÆ·Éú²úÏß¡£
ÉîÛÚbjlƽ̨¹ÈÉúÎïbjlƽ̨¹ÙÍøÒ©ÓÐÏÞ¹«Ë¾ °æÈ¨ËùÓРÔÁICP±¸2024168379ºÅ »¥ÁªÍøÒ©Æ·ÐÅÏ¢·þÎñ×ʸñÖ¤Ê飺(ÔÁ)-·Ç¾­ÓªÐÔ-2022-0426  ¼¼ÊõÖ§³Ö£ºÓѵãÈí¼þ
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿